Stem Cell Culture Metabolite Control Patents: Who Leads and Where the Gaps Are
62.5% of the 64 records in scope sit with just five assignees, with the leader alone holding 14 records. Filings peaked at 5 in 2019 and dipped afterward before recovering: 2021 held at 1 and climbed to 3 by 2024, a +200% increase over that three-year span. 2025 and 2026 show fewer records only because publication lags filing by roughly 18 months — those years are not yet complete and should not be read as a slowdown.
- 1THE RGT UNIV OF MICHIGAN14
- 2VCELL THERAPEUTICS INC12
- 3WAYNE STATE UNIV6
- 4AUCKLAND UNISERVICES LTD4
- 5THE CHINESE UNIVERSITY OF HONG KONG4
See the full stem cell culture metabolite control analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on this landscape
Who holds the most patents in stem cell culture metabolite control?
One assignee leads the field with 14 of the 64 records in scope, well ahead of the rest of the top five, which each hold closer to 4 records. Together the top five assignees account for 62.5% of all records, and the top ten reach 93.8%, so filing rights in this narrow area are concentrated among a small group of universities and biotech firms. A newcomer should expect to negotiate around this cluster's existing claims rather than find open ground at the very top of the ranking.
Is patent filing activity in this area growing or slowing down?
Filings grew from 1 in 2021 to 3 in 2024, a +200% increase over that three-year span, after an earlier peak of 5 filings in 2019. The apparent drop in 2025 and 2026 is a publication-lag artefact — patent publication typically trails filing by around 18 months, so the most recent one to two years are always undercounted. Based on the last fully complete years, the honest read is growth, not decline.
What technology areas are under-claimed in metabolite-controlled stem cell culture?
Biological method claims dominate: C12N classifications appear in 90.6% of the 64 records. Apparatus and monitoring classes are comparatively thin — C12M bioreactor and apparatus claims reach 32.8% and C12Q enzyme/DNA measurement claims only 9.4%. That gap suggests real-time sensing and closed-loop control hardware for lactate, ammonia, pH or redox state is less densely claimed than the underlying cell-culture biology, which is where a first-mover apparatus claim would have more room.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Stem Cell Culture Metabolite Control covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.